Merlin (NASDAQ: MRLN) posted third-quarter revenue of $3.5 million, up 80% from $1.9 million a year ago and 59% sequentially. It crushed the $2.2 million consensus estimate. The beat is real.
The headline GAAP net income of $73.8 million is not.

Strip out the $103.6 million non-cash gain from warrant revaluation and a different picture emerges. Adjusted EBITDA loss narrowed to $24.1 million from $27.8 million in Q2. Modest improvement. Higher revenue helped. So did some cost discipline.
The growth came from advancing defense contracts. The C-130J autonomy program with USSOCOM. A new Autonomous CASEVAC contract with USAFRICOM. The company ended the quarter with $161.6 million in cash and equivalents. No debt.
That warrant revaluation gain dominates the GAAP numbers. It is mark-to-market accounting. Zero cash impact. It will flip and flop each quarter with the stock price. The operating reality is simpler: a pre-revenue defense tech company burning cash to develop its Merlin Pilot autonomous flight system. Revenue still sits in single-digit millions. Operating expenses hit $29.7 million for the quarter.
R&D spending climbed to $14.7 million from $8.2 million a year ago. General and administrative costs more than doubled to $12.9 million. Selling and marketing jumped to $2.0 million from $0.3 million. The company is pouring money into program execution and business development. Appropriate, given funded contracts and a visible path to production revenue. But the cost base is outpacing revenue growth. An adjusted EBITDA loss of $24.1 million on $3.5 million of revenue speaks for itself. Profitability remains distant.
The $8.9 million task order for the next C-130J phase with USSOCOM matters most operationally. It pushes the program into integration, setting up future flight demonstrations and production revenue. The USAFRICOM Autonomous CASEVAC contract, at $500,000, is smaller but opens a new mission vertical. Merlin Pilot will run on a Cessna 208B Grand Caravan. These contracts prove the technology works and build a pipeline. They remain early-stage. The company cites over $100 million in IDIQ contract ceiling value under C-130J. Ceiling value is not revenue. It is an upper bound on what might be awarded.
Management has begun its 2027 planning process. The company expects to bring operating expenses "meaningfully below" 2026 levels by focusing investment on funded programs. This pivot is necessary. The cash runway into 2029 without additional capital hinges on execution: winning task orders, converting pipeline to revenue, cutting costs simultaneously. The balance sheet looks healthy for a company at this stage. But a burn rate near $24 million per quarter in adjusted EBITDA losses, plus working capital demands, means cash will drift downward unless revenue accelerates materially.
The expense reduction guidance for 2027 is the signal worth watching. Management appears to recognize that the current cost structure cannot persist at present revenue levels. Whether defense contract growth can outpace cost cuts is the open question. C-130J is the most plausible driver of a revenue step-change. Production revenue remains future tense. For now, Merlin is a story of contract wins and cash discipline, not operating leverage. The Q3 beat is welcome. The path to self-sufficiency runs through program execution. Not through accounting gains.
